{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-like+peptide+1",
    "query": {
      "intervention": "Glucagon-like peptide 1"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 586,
    "total_pages": 59,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Glucagon-like+peptide+1&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T05:41:39.769Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06976853",
      "title": "Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn Disease (CD)"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Standard of care treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2025-05-13",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-10-02T05:41:39.769Z",
      "location_count": 3,
      "location_summary": "Beverly Hills, California • St Louis, Missouri • New York, New York",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06976853"
    },
    {
      "nct_id": "NCT05616013",
      "title": "Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity",
        "Obese",
        "Overweight or Obesity"
      ],
      "interventions": [
        {
          "name": "Bimagrumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 507,
      "start_date": "2022-11-16",
      "completion_date": "2025-06-14",
      "has_results": true,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-10-02T05:41:39.769Z",
      "location_count": 10,
      "location_summary": "Anniston, Alabama • Cullman, Alabama • Hialeah, Florida + 7 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Lake Worth",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05616013"
    },
    {
      "nct_id": "NCT07619508",
      "title": "Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obesity",
        "Overweight"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100000,
      "start_date": "2026-02-10",
      "completion_date": "2026-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-10-02T05:41:39.769Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07619508"
    },
    {
      "nct_id": "NCT06962280",
      "title": "A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes",
        "Obesity",
        "Overweight"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 465,
      "start_date": "2025-05-12",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-10-02T05:41:39.769Z",
      "location_count": 18,
      "location_summary": "Bonita, California • Escondido, California • Newport Beach, California + 15 more",
      "locations": [
        {
          "city": "Bonita",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06962280"
    },
    {
      "nct_id": "NCT06333496",
      "title": "Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Blood Sugar; High",
        "Overweight and Obesity",
        "Fat Burn",
        "Obesity",
        "Heart Health Markers"
      ],
      "interventions": [
        {
          "name": "GLP-1 Booster (GB)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Alpine Biotech LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2024-01-02",
      "completion_date": "2024-05-08",
      "has_results": false,
      "last_update_posted_date": "2024-12-05",
      "last_synced_at": "2026-10-02T05:41:39.769Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06333496"
    },
    {
      "nct_id": "NCT03235050",
      "title": "A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "MEDI0382 low dose",
          "type": "DRUG"
        },
        {
          "name": "MEDI0382 mid dose",
          "type": "DRUG"
        },
        {
          "name": "MEDI0382 high dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Liraglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 834,
      "start_date": "2017-08-02",
      "completion_date": "2019-06-14",
      "has_results": true,
      "last_update_posted_date": "2020-08-17",
      "last_synced_at": "2026-10-02T05:41:39.769Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03235050"
    },
    {
      "nct_id": "NCT02014740",
      "title": "Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Overweight",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Liraglutide",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 100,
      "start_date": "2014-03",
      "completion_date": "2017-03",
      "has_results": true,
      "last_update_posted_date": "2019-06-06",
      "last_synced_at": "2026-10-02T05:41:39.769Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02014740"
    },
    {
      "nct_id": "NCT03258853",
      "title": "Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cystic Fibrosis-related Diabetes"
      ],
      "interventions": [
        {
          "name": "Bionic Pancreas",
          "type": "DEVICE"
        },
        {
          "name": "Usual Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2021-08-26",
      "completion_date": "2022-06-29",
      "has_results": true,
      "last_update_posted_date": "2023-07-20",
      "last_synced_at": "2026-10-02T05:41:39.769Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03258853"
    },
    {
      "nct_id": "NCT01388361",
      "title": "Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "insulin degludec",
          "type": "DRUG"
        },
        {
          "name": "insulin aspart",
          "type": "DRUG"
        },
        {
          "name": "liraglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 413,
      "start_date": "2011-09",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2017-03-06",
      "last_synced_at": "2026-10-02T05:41:39.769Z",
      "location_count": 48,
      "location_summary": "Concord, California • La Jolla, California • Lancaster, California + 44 more",
      "locations": [
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01388361"
    },
    {
      "nct_id": "NCT03480022",
      "title": "Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pre Diabetes",
        "Polycystic Ovary Syndrome",
        "Obesity Android"
      ],
      "interventions": [
        {
          "name": "Liraglutide Pen Injector [Saxenda]",
          "type": "DRUG"
        },
        {
          "name": "Placebo Liraglutide Pen Injector",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Woman's",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 88,
      "start_date": "2018-09-26",
      "completion_date": "2021-05-19",
      "has_results": true,
      "last_update_posted_date": "2021-06-07",
      "last_synced_at": "2026-10-02T05:41:39.769Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03480022"
    }
  ]
}